- Home
- NBBK vs EOLS Comparison
NBBK vs EOLS Comparison
Compare NBBK & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- EOLS
- Stock Information
- Founded
- NBBK 1892
- EOLS 2012
- Country
- NBBK United States
- EOLS United States
- Employees
- NBBK N/A
- EOLS N/A
- Industry
- NBBK
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- NBBK
- EOLS Health Care
- Exchange
- NBBK Nasdaq
- EOLS Nasdaq
- Market Cap
- NBBK 783.2M
- EOLS 787.7M
- IPO Year
- NBBK N/A
- EOLS 2018
- Fundamental
- Price
- NBBK $18.65
- EOLS $11.35
- Analyst Decision
- NBBK Buy
- EOLS Strong Buy
- Analyst Count
- NBBK 1
- EOLS 6
- Target Price
- NBBK $22.00
- EOLS $22.60
- AVG Volume (30 Days)
- NBBK 166.1K
- EOLS 509.1K
- Earning Date
- NBBK 10-30-2024
- EOLS 11-06-2024
- Dividend Yield
- NBBK N/A
- EOLS N/A
- EPS Growth
- NBBK N/A
- EOLS N/A
- EPS
- NBBK 0.30
- EOLS N/A
- Revenue
- NBBK $146,994,000.00
- EOLS $248,326,000.00
- Revenue This Year
- NBBK N/A
- EOLS $33.43
- Revenue Next Year
- NBBK N/A
- EOLS $32.44
- P/E Ratio
- NBBK $63.04
- EOLS N/A
- Revenue Growth
- NBBK 11.94
- EOLS 34.42
- 52 Week Low
- NBBK $13.10
- EOLS $9.80
- 52 Week High
- NBBK $21.05
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- NBBK 37.77
- EOLS 37.65
- Support Level
- NBBK $18.50
- EOLS $10.63
- Resistance Level
- NBBK $20.72
- EOLS $11.83
- Average True Range (ATR)
- NBBK 0.60
- EOLS 0.50
- MACD
- NBBK -0.20
- EOLS 0.00
- Stochastic Oscillator
- NBBK 6.76
- EOLS 31.38
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.